

Monoclonal Antibodies: A Manual of Techniques

Author

Heddy Zola



Monoclonal Antibodies: A Manual of Techniques

Author

Heddy Zola

Department of Clinical Immunology

Flinders Medical Centre

and

Flinders University of South Australia

Bedford Park,

Australia



CRC Press, Inc.
Boca Raton, Florida

Immunology

Antibodies

Hybridomas

Recombinant

Library of Congress Cataloging-in-Publication Data

Zola, Heddy.

Monoclonal antibodies.

Includes bibliographies and index.

1. Antibodies, Monoclonal.
 2. Immunology—Technique.
- I. Title. [DNLM: 1. Antibodies, Monoclonal.
2. Hybridomas. 3. Immunologic Technics. QW 585 Z86m]
QR186.85.Z65 1987 616.07'93 86-18394
ISBN 0-8493-6476-0

This book represents information obtained from authentic and highly regarded sources. Reprinted material is quoted with permission, and sources are indicated. A wide variety of references are listed. Every reasonable effort has been made to give reliable data and information, but the author and the publisher cannot assume responsibility for the validity of all materials or for the consequences of their use.

All rights reserved. This book, or any parts thereof, may not be reproduced in any form without written consent from the publisher.

Direct all inquiries to CRC Press, Inc., 2000 Corporate Blvd., N.W., Boca Raton, Florida, 33431.

© 1987 by CRC Press, Inc.

International Standard Book Number 0-8493-6476-0

Library of Congress Card Number 86-18394
Printed in the United States

PREFACE

In the past 10 years since the original description of antibody production by a somatic cell hybrid line, monoclonal antibodies have become standard reagents in many biological applications. There have been few major changes in the techniques used to make and to utilize monoclonal antibodies, and the mechanism of hybridization is still not understood in any detail. However, a few years of experience with the techniques have brought about important refinements, and have established a body of data which allows choices to be made between some of the alternative procedures. The production and use of monoclonal antibodies can, as a result, proceed in a fairly predictable way, provided that the best techniques are chosen for the particular objectives of the project. This book describes, in detail, techniques for the production and use of monoclonal antibodies. Methods are set out in the form of experimental protocols, so that the book can serve as a laboratory manual. The rationale behind each method is discussed, where appropriate. Where several alternative methods are available, a rational basis is provided, where possible, for the choice of methods appropriate to the reader's own needs. The book does not set out to review specific fields of use, however, since it is intended to cover in detail those aspects of interest to all scientists working with monoclonal antibodies.

The book is divided into three main parts. Part I covers the production of monoclonal antibodies, and includes chapters on the selection of donor cells, the fusion of cells, the screening of hybridomas, and the production of monoclonal antibodies. Part II covers the use of monoclonal antibodies, and includes chapters on the purification of monoclonal antibodies, the detection of monoclonal antibodies, and the application of monoclonal antibodies to various fields of research and development. Part III covers the future of monoclonal antibodies, and includes chapters on the development of new technologies for monoclonal antibody production, and the potential applications of monoclonal antibodies in medicine and industry.

This book is intended for researchers and practitioners in the field of monoclonal antibody production and use. It is also intended for students and postgraduates who are interested in the field. The book is written in a clear and concise style, and is designed to be accessible to a wide range of readers. The book is also intended to be useful for those who are involved in the development of new technologies for monoclonal antibody production, and for those who are interested in the potential applications of monoclonal antibodies in medicine and industry. The book is also intended to be useful for those who are involved in the regulation of monoclonal antibody production and use, and for those who are involved in the development of new regulations for monoclonal antibody production and use.

ACKNOWLEDGMENTS

This book is principally concerned with methodology. The techniques described have been used in projects which I have either directed or participated in. However, many of my colleagues have contributed in important ways, either with ideas or by doing the actual work. Current or former higher-degree students (Doug Brooks, Ian Beckman, and Russell Hogg), research assistants (Peter McNamara, Ian Hunter, Helen Moore, Joe Webster, and Angela Potter), and Hospital Scientists (Miriam Thomas, Pete Macardle, and Virginia Griffith) have done much of the work which serves as a base for this book. Scientific colleagues who have contributed ideas and suggestions, and have taught me some of the methods, include Drs. Anthony Hodgson, Sim Hee Neoh, Keryn Williams, John Bradley, and Art Hohmann. Professor John Bradley, Head of the Department of Clinical Immunology, has provided an environment which made the research possible, and has given active encouragement and support to research in his Department.

I prepared the early draft of this book on an Apple (and an Apple look-alike) and I owe a real debt to Messrs. Jobs and Wozniak. Writing books must have been such hard work in the days before microcomputers for the masses. My drafts, together with a multitude of alterations, were converted to the finished manuscript by Mary Brown, whose diligence and careful work is greatly appreciated. The art-work was produced by Dennis Jones of the Media and Illustration Unit, Flinders Medical Centre, and by Adrian Wright and Angela Potter. The photographs are my own, but my colleagues had to wait patiently with syringe or scalpel poised, while I fiddled with the focus or the flash.

Dr. Anthony Hodgson read a later draft and provided valuable criticism, particularly of the sections dealing with immunohistochemistry, an area in which his expertise is much greater than mine. Dr. Sim Neoh provided details for the immunoglobulin purification methods of Chapter 4. Dr. Keryn Williams read the whole book in draft form, and provided extensive and valuable critical comments on the scientific content, the clarity, and the English. It is all too easy to write text which is quite clear to the writer, and totally unclear to the reader. If this book turns out to be readable, this will be due, in large measure, to Keryn Williams' constructive criticism. Having sought the help and advice of my colleagues, I chose to ignore some of their comments. The responsibility for any residual flaws is therefore squarely mine.

THE AUTHOR

Heddy Zola is Chief Hospital Scientist in the Department of Clinical Immunology, Flinders Medical Centre, and Reader in Immunology in the Flinders University of South Australia. He received a Bachelor of Science degree in Chemistry from the University of Birmingham, in England, and a Doctor of Philosophy degree in Biophysics, from the University of Leeds, England.

Following his Ph.D. studies Dr. Zola worked in the Biophysics Department of Leeds University, before joining the Wellcome Research Laboratories, Beckenham, Kent, where he carried out biophysical and biochemical studies on a variety of biologically active proteins. Involvement in a project aimed at the preparation of antilymphocyte serum, for the use in the treatment and prevention of transplant rejection in man, led to an interest in the immunology of the lymphocyte surface. When Kohler and Milstein described the first hybridoma, the potential of this technique as a tool in studies of cell membrane molecules soon became apparent. Dr. Zola started to make monoclonal antibodies against human lymphocyte antigens, initially at Wellcome and subsequently in Australia.

Dr. Zola was born and grew up in Africa, where his parents had settled as refugees from Europe. After attending schools in Zanzibar and Kenya, he went to England in 1959, initially to study, married and stayed on in England until 1978. The lure of sunshine and open spaces eventually proved irresistible, and Dr. Zola, his wife Marion, and their two daughters moved to Australia, where they live in the city of Adelaide.

TABLE OF CONTENTS

| | |
|---|----|
| Chapter 1 | |
| Introduction..... | 1 |
| I. Aim and Scope of This Book | 1 |
| II. Antibody as a Specific Probe | 1 |
| III. Monoclonal Antibody | 3 |
| IV. Monoclonal and Polyclonal Antibody Compared | 5 |
| A. One Antibody or Many Different Antibodies..... | 5 |
| B. Different Antibodies Against the Same Antigen | 6 |
| C. Single or Multiple Antigenic Epitopes | 6 |
| D. Recognition of Patterns Consisting of Several Antigenic Determinants..... | 6 |
| E. Sensitivity and Specificity..... | 8 |
| F. Labile Epitopes..... | 8 |
| G. Labile Antibodies..... | 8 |
| H. Affinity..... | 8 |
| I. Cross Reactivity | 9 |
| V. Monoclonal Antibodies as Standard Reagents..... | 9 |
| VI. Comments on Publication, Supply, and Commercialization of Monoclonal Antibodies | 10 |
| References | 11 |
| Chapter 2 | |
| Overview | 13 |
| I. Aim of the Chapter..... | 13 |
| II. Applications and Limitations of Monoclonal Antibodies (Do I Need Monoclonals, and What Can I Realistically Expect to Do With Them?) | 13 |
| A. Identification and Quantitation of a Soluble Molecule in a Mixture | 14 |
| B. Purification of a Soluble Molecule from a Mixture | 15 |
| C. Detection and Quantitation of a Cell Type in Suspension | 15 |
| D. Separation of a Particular Cell Type from a Mixture | 16 |
| E. Identification of Molecular and Cellular Structures in Tissue..... | 16 |
| F. Clinical Applications..... | 16 |
| III. Availability (Shall I Make My Own Monoclonal Antibodies or Can I Obtain Them?)..... | 17 |
| IV. Resources Needed to Make Monoclonal Antibodies | 17 |
| A. Major Equipment..... | 17 |
| 1. Cabinet for Sterile Work..... | 17 |
| 2. Gassed Incubator | 18 |
| 3. Liquid Nitrogen Facility..... | 18 |
| 4. Animal House | 18 |
| B. Minor Equipment..... | 18 |
| C. Staff and Skills Required | 18 |
| References | 19 |
| Further Reading..... | 21 |

| | |
|---|-----------|
| Chapter 3 | |
| Making Hybridomas | 23 |
| I. Scope of the Chapter..... | 23 |
| II. Strategy | 23 |
| III. Materials to be Ordered | 24 |
| A. Quantities Needed | 24 |
| B. Description..... | 26 |
| 1. Cell Culture Medium: RPMI 1640 or Equivalent | 26 |
| 2. Fetal Calf Serum (FCS) or Other Serum | 26 |
| 3. HAT Selective Medium Components | 27 |
| 4. Dimethyl Sulfoxide..... | 27 |
| 5. Polyethylene Glycol (PEG)..... | 27 |
| IV. Stock and Working Solutions..... | 27 |
| A. Medium | 27 |
| B. HAT Medium..... | 28 |
| C. HT Medium | 28 |
| D. Gey's Hemolytic Medium..... | 28 |
| 1. Gey's Solution A..... | 28 |
| 2. Gey's Solution B | 28 |
| 3. Gey's Solution C..... | 29 |
| 4. Working Solution..... | 29 |
| E. Phosphate-Buffered Saline (PBS)..... | 29 |
| F. PEG/DMSO Fusing Agent Solution | 29 |
| V. Immunization..... | 29 |
| A. The Antibody Response..... | 30 |
| B. A "Typical" Immunization Protocol..... | 30 |
| C. List of Variables | 31 |
| D. Detailed Analysis of Variables..... | 31 |
| 1. Choice of Animal..... | 31 |
| 2. Antigen..... | 31 |
| 3. Dose, Adjuvant, Route..... | 31 |
| 4. Booster Injections | 32 |
| 5. Improving Specificity | 32 |
| 6. Serum Antibody to Assess Immunization..... | 35 |
| 7. Local Immune Stimulation | 35 |
| VI. Hybridization | 35 |
| A. The Myeloma Cell Line | 36 |
| B. Spleen Cells | 37 |
| C. The Fusion Process..... | 38 |
| 1. Introduction and Rationale..... | 38 |
| 2. Materials and Preparation | 38 |
| 3. Procedure..... | 39 |
| 4. Notes..... | 42 |
| VII. Maintenance and Propagation..... | 44 |
| A. Introduction and Rationale..... | 44 |
| B. Culture of Hybrids after Fusion..... | 46 |
| VIII. Screening..... | 49 |
| A. Introduction and Rationale..... | 49 |
| 1. Primary and Secondary Interactions | 49 |
| 2. Single and Multiple Determinants | 50 |

| | | |
|------------------------|---|----|
| 3. | The Prozone Phenomenon | 50 |
| 4. | Sensitivity and Background Staining | 50 |
| 5. | Speed and Convenience | 51 |
| B. | Specific Applications and Examples | 52 |
| 1. | Particulate Antigens | 52 |
| a. | Indirect Immunofluorescence | 52 |
| b. | Staining of Tissue Sections, Cell Smears, or Cytocentrifuge Preparations | 52 |
| c. | Cell ELISA, Immunofixation, Isotopically Labeled Antiummunoglobulin Methods, and Rose-Bengal Assay | 53 |
| 2. | Soluble Antigens | 53 |
| 3. | Commercial Screening Reagents | 54 |
| IX. | Cloning | 54 |
| A. | Introduction and Rationale | 54 |
| B. | Methods | 54 |
| 1. | Cloning by Limiting Dilution | 54 |
| a. | Rationale | 54 |
| b. | Materials | 55 |
| c. | Procedure | 55 |
| 2. | Semisolid Agar Cloning | 56 |
| 3. | Cloning and Selection by Flow Sorting | 56 |
| X. | Cryopreservation | 56 |
| A. | Introduction and Rationale | 56 |
| B. | Freezing Cells Down | 57 |
| 1. | Note | 57 |
| C. | Thawing Cells Out | 58 |
| 1. | Notes | 58 |
| XI. | Problem Solving | 58 |
| References | | 59 |
| Further Reading | | 61 |

Chapter 4

Monoclonal Antibodies: Production, Purification, Analysis, Quality Control, Storage, and Distribution

| | | |
|------------|--|----|
| I. | Introduction | 63 |
| II. | Production | 63 |
| A. | Tissue Culture Production | 63 |
| 1. | Scale | 63 |
| 2. | Medium | 64 |
| 3. | Sterility | 64 |
| a. | Sterility Testing | 64 |
| b. | Identification of Contaminants | 65 |
| c. | Additional Antibiotics | 65 |
| B. | Production in Animals | 66 |
| 1. | Rationale | 66 |
| 2. | Procedure: Production of Ascitic Fluid in BALB/c Mice | 67 |
| a. | Mice | 67 |
| b. | Pristane | 67 |
| c. | Hybridoma | 67 |

| | | |
|------------------------|--|----|
| d. | Harvesting | 67 |
| e. | Processing of Ascites | 68 |
| f. | Storage | 70 |
| III. | Purification | 70 |
| A. | Rationale | 70 |
| B. | PEG Precipitation | 72 |
| 1. | Principle | 72 |
| 2. | Materials | 72 |
| 3. | Procedure | 72 |
| 4. | Notes | 73 |
| C. | Ion Exchange Method | 74 |
| 1. | Materials | 74 |
| 2. | Procedure | 75 |
| 3. | Notes | 75 |
| D. | Protein A Method | 75 |
| 1. | Materials | 75 |
| 2. | Procedure | 76 |
| IV. | Analysis and Quality Control | 76 |
| A. | Protein Concentration | 76 |
| 1. | UV Absorption | 76 |
| 2. | Biuret Method | 77 |
| a. | Materials | 77 |
| b. | Method | 77 |
| c. | Notes | 77 |
| B. | Antibody Concentration | 77 |
| 1. | Introduction and Rationale | 77 |
| 2. | Determination of Mouse Immunoglobulin by ELISA | 78 |
| a. | Materials | 78 |
| b. | Procedure | 78 |
| 3. | Determination of Monoclonal Immunoglobulin by Zone Electrophoresis and Measurement of Total Protein | 79 |
| C. | Monoclonality | 79 |
| 1. | Introduction and Rationale | 79 |
| 2. | Tests on the Antibody | 80 |
| a. | Chain Composition | 80 |
| b. | Electrophoretic Identification of Chains | 80 |
| 3. | Analysis of the Hybridoma Line | 81 |
| 4. | Effect of Recloning | 81 |
| 5. | Example: Monoclonality of FMC3 | 82 |
| D. | Immunoglobulin Chain Identification | 83 |
| 1. | Introduction | 83 |
| 2. | Method | 83 |
| a. | Materials | 83 |
| b. | Procedure | 84 |
| 3. | Notes | 84 |
| V. | Storage and Stability, Distribution | 84 |
| A. | Storage and Stability | 84 |
| B. | Distribution | 85 |
| References | | 86 |
| Further Reading | | 87 |

| | | |
|--|---|------------|
| Chapter 5 | | |
| Using Monoclonal Antibodies: Cell and Tissue Markers..... | 89 | |
| I. | Introduction..... | 89 |
| II. | Identification and Enumeration of Cells in Suspension | 89 |
| A. | Immunofluorescence..... | 89 |
| 1. | Principles | 89 |
| 2. | Methods: Indirect Immunofluorescence of Separated Blood Cells with Monoclonal Antibodies | 93 |
| a. | Warning..... | 93 |
| b. | Materials | 93 |
| c. | Procedure..... | 94 |
| d. | Notes..... | 94 |
| B. | Flow Cytometry: Principles | 97 |
| C. | Counting Cell Populations Using Monoclonal Antibodies..... | 99 |
| D. | Quantitation of Cellular Antigen | 102 |
| 1. | Comparison of Cells Within a Population and Between Populations | 102 |
| 2. | Antigen Biochemistry | 102 |
| 3. | Additive Binding | 103 |
| E. | Rosetting Methods..... | 103 |
| F. | Cytotoxicity | 104 |
| 1. | Principles | 104 |
| 2. | Dye Exclusion (Trypan Blue) | 105 |
| a. | Materials | 105 |
| b. | Method | 105 |
| c. | Notes..... | 106 |
| 3. | Fluorescein Diacetate Method | 106 |
| a. | Materials | 106 |
| b. | Procedure..... | 107 |
| c. | Notes..... | 108 |
| d. | Example..... | 108 |
| 4. | Methods for Proliferating Cells | 108 |
| 5. | Chromium Release Method | 109 |
| a. | Materials | 109 |
| b. | Procedure..... | 109 |
| c. | Notes..... | 109 |
| G. | Dual Marker Methods | 110 |
| III. | Tissue Sections, Smears, and Cytocentrifuge Preparations..... | 112 |
| A. | Types of Tissue Preparation | 113 |
| 1. | Blood Smears | 113 |
| 2. | Cytocentrifuge Preparations | 113 |
| 3. | Tissue Sections | 114 |
| B. | Fixatives..... | 114 |
| C. | Staining Methods | 115 |
| 1. | Introduction..... | 115 |
| 2. | Immunoenzyme Methods | 116 |
| 3. | Particulate Markers — Silver-Intensified Gold Labeling | 118 |
| D. | Electron Microscopy | 118 |
| E. | Examples..... | 118 |
| 1. | Introduction..... | 118 |

| | | |
|------------|---|-----|
| 2. | Equipment and Materials Common to Several Methods; | |
| | Stock Solutions..... | 119 |
| a. | Equipment..... | 119 |
| b. | Buffers and Solutions..... | 119 |
| 3. | Example 1: Staining of Cytocentrifuge Preparations for Cytoplasmic Immunoglobulin by an Immunoperoxidase Method | 121 |
| a. | Materials | 121 |
| b. | Procedure..... | 122 |
| c. | Notes..... | 122 |
| 4. | Example 2: Staining of Tissue Sections Using Alkaline-Phosphatase-Antialkaline Phosphatase..... | 122 |
| a. | Materials | 123 |
| b. | Procedure..... | 123 |
| 5. | Example 3: Staining at EM Level with Protein-A Gold..... | 124 |
| a. | Materials | 125 |
| b. | Procedure..... | 125 |
| 6. | Example 4: Staining of Blood Cells with Monoclonal Antibodies for Light Microscopy Using Silver-Intensified Protein-A Gold..... | 125 |
| a. | Materials | 126 |
| b. | Procedure..... | 126 |
| IV. | Cell Separation | 126 |
| A. | Principles of Separation | 127 |
| B. | Assessment of Separation and Optimization of Conditions | 128 |
| C. | Flow Sorting | 128 |
| D. | Immunoaffinity Columns, Panning, Rosetting, and Magnetic Separation | 129 |
| E. | Examples of Monoclonal Antibody-Based Cell Separations..... | 131 |
| 1. | Separation of Blood Mononuclear Cells from Polymorphs Using the Polymorph-Reactive Monoclonal Antibody FMC13..... | 131 |
| 2. | Enrichment of B Cells for HLA-Dτ Typing by Panning with Antihuman IgG Antibody | 132 |
| 3. | Depletion of Leukemic Lymphocytes from a Blood Cell Mixture by Separation with Monoclonal Antibody on Magnetic Microparticles..... | 134 |
| a. | Materials | 134 |
| b. | Preparation of Coated Magnetic Beads | 135 |
| c. | Labeling of Cells | 135 |
| d. | Procedure | 135 |
| | Results | 135 |
| F. | Preparative Cytotoxicity | 135 |
| 1. | Introduction..... | 135 |
| 2. | Procedure..... | 136 |
| 3. | Notes..... | 136 |
| V. | Preparation of Specialized Reagents for Use in Cell and Tissue Staining and Separation..... | 136 |
| A. | Preparation of Goat-Antimouse Immunoglobulin and Fluorescein Conjugate..... | 136 |

| | | |
|----------------------|---|-----|
| 1. | Introduction | 136 |
| 2. | Preparation of Mouse Immunoglobulin (M Ig) | 137 |
| 3. | Immunization of Goat | 137 |
| 4. | Processing of GaM Ig | 137 |
| 5. | Fluorescein Conjugation | 138 |
| 6. | Quality Control | 139 |
| a. | Fluorescein/Protein Ratio | 139 |
| b. | Staining and Background | 139 |
| 7. | Absorption | 139 |
| B. | Affinity Purification of GaM Ig | 139 |
| 1. | Rationale | 139 |
| 2. | Method | 140 |
| 3. | ELISA for Mouse-Ig-Binding Activity | 140 |
| C. | Biotinylation of GaM Ig | 141 |
| 1. | Rationale | 141 |
| 2. | Materials | 141 |
| 3. | Procedure | 141 |
| 4. | Testing | 141 |
| D. | Preparation of Colloidal Gold-Protein A | 142 |
| 1. | Introduction | 142 |
| 2. | Materials | 142 |
| 3. | Procedure | 142 |
| 4. | Notes | 143 |
| | References | 143 |
| | Further Reading | 145 |
| Chapter 6 | | |
| | Using Monoclonal Antibodies: Soluble Antigens | 147 |
| I. | Introduction | 147 |
| II. | Immunoassay: Determination of the Concentration of an Antigen in a Mixture | 147 |
| A. | General Discussion | 147 |
| B. | Enzyme-Linked Immunoassay (ELISA) — Technical Aspects | 150 |
| 1. | Introduction | 150 |
| 2. | Materials | 151 |
| a. | ELISA Plates | 151 |
| b. | ELISA Plate Reader | 151 |
| c. | Buffers | 151 |
| d. | Antibodies | 152 |
| e. | Detection Reagents | 152 |
| 3. | Method | 152 |
| 4. | Notes | 153 |
| a. | Checkerboard Titrations to Establish Optimal Concentrations | 153 |
| b. | Incubation Times | 154 |
| c. | Alternative Detection Systems | 154 |
| d. | Modification of ELISA for the Detection of Antibody | 154 |
| C. | Dot Immunoblotting on Nitrocellulose | 154 |

| | | |
|-------------|---|-----|
| 1. | Introduction..... | 154 |
| 2. | Materials..... | 157 |
| 3. | Method..... | 157 |
| 4. | Notes..... | 158 |
| | a. Alternative Detection Systems..... | 158 |
| | b. Alternative Blocking Solutions..... | 158 |
| III. | Biological Activity: Relationship of Biologically Active Site to Immunogenic Epitope | 158 |
| IV. | Immunochemical Characterization of the Antigen Reacting with a Monoclonal Antibody | 158 |
| A. | Introduction..... | 158 |
| B. | Principles of the Methods Used | 159 |
| 1. | Nature of the Antigen | 159 |
| 2. | Protein Molecular Weight and Characterization | 160 |
| | a. Electrophoresis in Gel | 160 |
| | b. Probing for the Antigen — Electrophoretic Blotting..... | 161 |
| | c. Prior Purification of the Antigen — Immunoprecipitation and Immunoaffinity Purification | 162 |
| 3. | Lipid Antigens..... | 163 |
| 4. | Carbohydrate Antigens..... | 163 |
| C. | Methods..... | 163 |
| 1. | Radiolabeling | 163 |
| | a. Iodination — Chloramine T..... | 163 |
| | i. Principle | 163 |
| | ii. Materials | 163 |
| | iii. Method | 164 |
| | iv. Notes..... | 164 |
| | b. Iodination — Iodo-gen | 165 |
| | i. Materials | 165 |
| | ii. Method | 166 |
| | iii. Notes..... | 166 |
| | c. ³⁵S Methionine Incorporation | 166 |
| | i. Materials | 166 |
| | ii. Method | 166 |
| | iii. Notes..... | 167 |
| 2. | Immune Precipitation..... | 167 |
| | a. Membrane Extracts..... | 167 |
| | i. Materials | 167 |
| | ii. Method | 168 |
| | iii. Notes..... | 168 |
| | b. Soluble Proteins | 169 |
| 3. | Affinity Column | 169 |
| 4. | Polyacrylamide Gel Electrophoresis | 170 |
| | a. Electrophoresis | 170 |
| | i. Materials | 170 |
| | ii. Method | 170 |
| | b. Staining and Antigen Detection Methods | 172 |
| | i. Coomassie Blue Staining | 172 |
| | ii. Silver Stain | 172 |

| | | |
|--|--|------------|
| iii. | Autoradiography for ^{125}I | 172 |
| iv. | Fluorography for ^{35}S or ^3H | 173 |
| v. | Electrophoretic Blotting..... | 173 |
| V. | Purification: Affinity Separation Based on Monoclonal Antibody..... | 174 |
| A. | Introduction..... | 174 |
| B. | Detailed Consideration of Variables | 175 |
| 1. | Antigen Source | 175 |
| 2. | Choice of Antibody | 176 |
| 3. | Choice of Affinity Matrix | 176 |
| 4. | Choice of Coupling Method..... | 176 |
| 5. | Column Parameters | 177 |
| 6. | Wash Buffers | 178 |
| 7. | Elution Buffer | 178 |
| 8. | Regeneration and Reuse of the Column..... | 179 |
| References..... | 179 | |
| Further Reading..... | 181 | |
| Chapter 7 | | |
| Prospects, Problems, and Limitations in the Use of Monoclonal Antibodies..... | | 183 |
| I. | Scope of the Chapter..... | 183 |
| II. | Monoclonal Antibodies as Reproducible Reagents | 183 |
| III. | Comparison of Different Monoclonal Antibodies for the Same Use | 184 |
| IV. | Diagnostic Reagents..... | 185 |
| V. | Therapeutic Use of Monoclonal Antibodies..... | 186 |
| A. | Introduction..... | 186 |
| B. | Monoclonal Antibodies in Cancer | 187 |
| 1. | The Question of Specificity..... | 187 |
| 2. | Mechanisms of Action..... | 188 |
| 3. | Diagnostic Tumor Imaging..... | 189 |
| C. | Monoclonal Antibodies in Transplantation | 189 |
| 1. | Organ Transplantation | 189 |
| 2. | Ex Vivo Treatment of Bone Marrow for Transplantation | 189 |
| VI. | Human Monoclonal Antibodies..... | 190 |
| References | 191 | |
| Appendix 1 | | |
| Sources of Information on Existing Hybridomas | | 193 |
| I. | Special Journals and Hybridoma Listings | 193 |
| II. | American Type Culture Collection (ATCC)..... | 193 |
| Appendix 2 | | |
| Manufacturers and Suppliers of Equipment, Materials, and Reagents | | 195 |
| I. | Classified Directory | 195 |
| II. | Alphabetical Listing with Addresses | 197 |

| | |
|---|-----|
| Appendix 3 | |
| Laboratory Hazards..... | 199 |
| Appendix 4 | |
| Buffers and Reagents | 201 |
| I. Buffers | 201 |
| A. General Comments | 201 |
| B. Buffer Tables | 201 |
| C. Making Up and Keeping | 201 |
| II. Reagents | 201 |
| A. Calculation of Dilutions..... | 202 |
| B. Weighing Out Reagents | 202 |
| Appendix 5 | |
| Units and Prefixes | 203 |
| I. Radioactivity..... | 203 |
| II. Prefixes and Symbols for Multiples of Units..... | 203 |
| Index | 205 |

Chapter 1

INTRODUCTION

I. AIM AND SCOPE OF THIS BOOK

The first publication describing the preparation of a monoclonal antibody by somatic cell hybridization appeared in 1975.¹ Less than a decade later, in 1984, the authors of that paper (Kohler and Milstein) have shared a Nobel Prize, and monoclonal antibodies are regularly mentioned in the lay press. The layman really does not need to know much about monoclonal antibodies; they are high technology, the product of genetic engineering, used in making magic bullets, and quite definitely "a good thing."

On the other hand, biological and medical scientists in a variety of disciplines do need to know much more about monoclonal antibodies, and if they are not immunologists (and, perhaps, even if they are) they may need some help. Monoclonal antibodies are available for use, or at least talked about, in a variety of fields, from cancer diagnosis to the food industry; from transplant surgery to plant pathology. The scientist in any biological or medical field may need to answer these questions:

- Do I need monoclonals?
- Do I need to make them myself?
- How do I use them?
- What can I realistically expect from them?

This book is intended to enable biologists and medical scientists to answer such questions for themselves, in the context of their own particular needs. The book provides detailed methodology to enable readers to make their own antibodies and to use monoclonal antibodies to their best advantage.

II. ANTIBODY AS A SPECIFIC PROBE

Antibodies are proteins made by many animal species as part of the specific immune response to foreign substances. Specificity is the hallmark of the immune response; recovery from measles leads to lifelong immunity from measles, but confers no protection against chicken pox. One component of this specific response is the synthesis, by B lymphocytes and plasma cells, of antibody which reacts with a high affinity with the stimulating substance (the antigen), but not with other substances. This natural ability to make proteins with a high order of specificity in distinguishing different molecular structures can be used in a variety of ways. Antibody obtained by injecting a rabbit with human insulin reacts specifically with human insulin and can be used as a probe for the hormone. The antibody can serve as the basis for a quantitative assay for the hormone; it can be used to detect cells secreting the hormone in tissue sections; it can be used to purify the hormone from a complex mixture of proteins. Thus, antibodies have long been used as reagents in the detection, measurement, and purification of biological molecules. Antibodies have also been used for treatment; antibody made in horses against bacterial toxins or snake venoms provides emergency treatment, albeit with considerable risk of an adverse immune reaction to the horse antibody, itself seen as a foreign molecule by the immune system of the patient.

Until recently such antibodies were obtained by immunizing an animal and then bleeding it. The antibodies are secreted into the serum, and the protein fraction con-